CD68 and neoplasm: In conclusion, using our cTA analysis of PD-L1 immunostaining relative to immune biomarkers that might be involved in NSCLC immune surveillance during this late disease stage, we demonstrated that groups with high levels of PD-L1 defined by cut-off points of 25 and 50% enriched also for higher amounts of FOxP3, CD8, Granzyme B, and CD68 positive cells in tumor-nest and TME.